This Was a Big Week for Weed, but the Future's Looking More Lucrative Than Ever

Our grandkids (no doubt flush with comfortable inheritances) may not ever realize that Wednesday, Oct. 17, 2018, was the day "everything changed."

That was, of course, the day recreational "adult use" sales of cannabis became legal in Canada - the world's 10th largest economy and the first G7 member to completely legalize the green stuff.

This was a historic moment and a massive profit catalyst for weed investors.

And in a way, "Green Wednesday" was the start of a high-profit journey, not the end. Because, to be clear, Canada's bold move is a key part of a growing global trend.

Soon, markets around the world, including the United States, will be opening up as the end of marijuana prohibition plays out over the next few years.

Former Speaker of the House: “Forget Canada, American Cannabis Is Where the Action Is Going to Be” – Click Here for Details

No wonder Grand View Research forecasts the global cannabis sector will be worth $146.4 billion by 2025. And Deloitte says the Canadian market alone could be worth $22.6 billion in the next several years.

Big business sees the profit potential in Canada as well.

[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]

Constellation Brands Inc. (NYSE: STZ) announced plans in August to invest $3.8 billion in the Canadian cannabis firm Canopy Growth Corp. (NASDAQ: CGC). Constellation is the $43 billion beverage giant behind Corona beer, Robert Mondavi wines, Svedka vodka, and many other well-known brands.

Since that mid-August announcement - in just two months - some of my favorite weed stocks have absolutely exploded.

  • Canopy is up 105%.
  • Aurora Cannabis Inc. (OTC: ACBFF) is up 157.8%.
  • Cronos Inc. (NYSE: CRON) is up 86.5%.
  • And Tilray Inc. (NASDAQ: TLRY) is up an astounding 508%.

The S&P 500 over the period has retreated 1.2%.

Of course, we may yet see some folks "selling the news" and sending pot stocks lower, but this is a very young business - and cannabis is a very long-term investment that will be making us rich for years to come.

This proves what I have been saying for some time now - legal cannabis is an unstoppable force that can make savvy investors a lot of money... if you have the right investing guide in your corner.

That said, while pot shops and e-commerce sites across Canada have opened up, it's not as many as hoped. And some customers... and investors... are feeling discouraged.

They shouldn't be...

Walmart Could Go "Weedmart"

Last week, Walmart Inc. (NYSE: WMT)'s Canadian division said it was exploring the possibility of selling cannabis-infused products in its stores.

While various global beverage and tobacco giants have been showing interest in the legal cannabis market, Walmart is the first big retailer to do so. And considering founder Sam Walton's conservative bona fides, that's probably the most surprising choice possible.

Earlier this year, the mega retailer greenlit the sale of American Cannabis Co.'s soil mix via their online store. While this isn't exactly the same as stocking their shelves with bud, it's a big step for the traditionally conservative retailer.

In the United States, cannabis is still illegal on the federal level, and Walmart doesn't want to make any bold stances that could anger its American shoppers. So instead of selling marijuana, it's looking into another popular sector of the marijuana market - cannabidiol, or CBD.

In Case You Missed It: Former Speaker of the House John Boehner was once marijuana’s biggest enemy… now he’s advising Americans to go “ALL IN” on cannabis. To see his shocking prediction, click here...

CBD is the non-psychoactive agent in marijuana. One CBD drug - a childhood epilepsy treatment from GW Pharmaceuticals Plc. (NASDAQ: GWPH) - just got reclassified as a Schedule 5 drug in the United States, on par with cough syrup. Many companies are looking into CBD-infused beverages to market as "health drinks" that could help with chronic pain and inflammation.

The marijuana industry was valued at $17.18 million according to a recent study by Genesis Market Insights. By 2023, it's expected to reach $59 billion.

So it's no surprise Walmart wants in on those profits.

Nobody wants to miss out on profits like these.

Least of all you...

An "Under the Radar" Catalyst

While Canada's legalization has been dominating marijuana headlines, there have been moves underway elsewhere in the market that haven't got as much attention as I'd like.

Canopy announced Monday that it plans to purchase Ebbu, a Colorado-based hemp company. Canopy says the acquisition will "complement and accelerate" its current research, as well as help with the development of new products.

Already, Canopy's stock rallied as much as 9% following the news of the acquisition - even in the face of other stocks getting slammed by those "selling the news." Canopy has agreed to pay Ebbu CA$25 million (US$19.1 million) for the "intellectual property and research and development advancements achieved by Ebbu's team."

Canopy is exploring a hemp and THC-rich cannabis genetic breeding program. It's also looking into cannabis-infused beverages. With Ebbu, it's hoping to speed up this process.

Ebbu specializes in the purification and study of CBD for product development, retail, and research. And that's exactly the type of knowledge Canopy needs to continue its work.

For consumers, it means new strains of marijuana. These different strains can have different effects on the body, from calming to energizing. Scientists playing with these components means new strands would hit the recreational and medical markets.

Its "drinkables" could be alcohol-free "marijuana beers" that get you high instead of drunk. They could also take the form of health drinks with anti-inflammatory and pain-relieving properties.

For investors in Canopy and other well-positioned weed firms, it means even bigger profits just around the corner.

See Why John Boehner Is Going “ALL IN” on Cannabis

Former Speaker of the House John Boehner just joined the cannabis industry’s biggest players to cover everything you need to know about America’s next unstoppable economic revolution.

At our live event, they explained how cannabis could become our next $1 trillion industry… every step to full legalization… how the average American can profit from this explosive phenomenon… and John Boehner’s SHOCKING marijuana prediction.

To see a full rebroadcast of this extraordinary event, click here.

Follow Money Morning on Facebook, Twitter, and LinkedIn.

About the Author

Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...

  • He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
  • He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
  • As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.

This all means the entire world is constantly seeking Michael's insight.

In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.

Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.

And even with decades of experience, Michael believes there has never been a moment in time quite like this.

Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.

To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.

His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.

Read full bio